Ofatumumab-associated colitis: A case report
- PMID: 39644146
- DOI: 10.1177/13524585241303479
Ofatumumab-associated colitis: A case report
Abstract
Background: Colitis has been reported with some anti-CD20 therapies in multiple sclerosis (MS), but not previously with ofatumumab.
Objectives: To report the first case of ofatumumab-associated colitis in MS and discuss its implications.
Methods: Case report.
Results: A 56-year-old female with relapsing-remitting multiple sclerosis (RRMS) developed severe colitis 3 months after initiating ofatumumab, requiring hospitalization and treatment discontinuation.
Conclusion: This case suggests a potential class effect of anti-CD20 therapies, including ofatumumab, in relation to colitis in MS. Clinicians should monitor for gastrointestinal symptoms in MS patients receiving any anti-CD20 therapy.
Keywords: Ofatumumab; adverse effect; anti-CD20 therapy; colitis; inflammatory bowel disease; multiple sclerosis.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
